{"id":"W2089311432","doi":"10.1182/blood-2012-05-425934","title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":655,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; University of Calgary; University of Toronto","funders":"National Cancer Institute; Jewish General Hospital; Onyx Pharmaceuticals; University of Alberta; Wake Forest University","keywords":"Carfilzomib; Multiple myeloma; Refractory (planetary science); Medicine; Pomalidomide; Lenalidomide; Oncology; Internal medicine; Materials science","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001171719,0.001441639,0.001797245,0.0004150797,0.000327659,0.0005490789,0.0006843164,0.001002092,0.003382487],"category_scores_gemma":[0.000630284,0.0004528907,0.0008602787,0.0003032401,0.0006524614,0.0005925098,0.0002824011,0.00198024,0.0006810595],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006431729,"about_ca_system_score_gemma":0.00121169,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007518679,"about_ca_topic_score_gemma":0.001778697,"domain_scores_codex":[0.9997316,0.0001146217,0.000009804813,0.00005348074,0.00003220671,0.00005828612],"domain_scores_gemma":[0.999561,0.00007543664,0.00008744613,0.00002707658,0.00002304867,0.0002260229],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5729035,0.1321645,0.0116318,0.001198575,0.001036432,0.001107777,0.0005864388,0.003819877,0.07944411,0.0004871304,0.006156135,0.1894637],"study_design_scores_gemma":[0.4308757,0.5435147,0.01538811,0.00002576699,0.0002647142,0.0007179359,0.00005755942,0.001785384,0.003964499,0.0001861933,0.0031912,0.00002806779],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928878,0.001472812,0.0005680483,0.0002658686,0.00006106021,0.002775102,0.000647817,0.0001071226,0.001214436],"genre_scores_gemma":[0.9861866,0.001868644,0.002254616,0.0007928513,0.0001844682,0.003342507,0.002526839,0.0000285535,0.002814798],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003382487,"threshold_uncertainty_score":0.01131552,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02848352810245834,"score_gpt":0.2876643652637208,"score_spread":0.2591808371612624,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}